Selective serotonin reuptake inhibitors and bone health

Elizabeth M. Haney, M. Michael Bliziotes

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Studies demonstrating lower bone mineral density among depressed patients have led to the investigation of antidepressant medications and bone health. It remains unclear whether the depressed state itself or antidepressant treatment is responsible for these findings. Several recent observations support a role for serotonin in bone health. Serotonin transporters have been documented in osteocytes, osteoblasts and osteoclasts. Mice with disruption of the serotonin transporter gene have an osteopenic phenotype. Cohort studies in humans have demonstrated lower bone mineral density, higher rates of bone loss and fracture among those using selective serotonin-reuptake inhibitors compared with those on other antidepressants (primarily tricyclic antidepressants) and those on no antidepressant medication. Areas of future research may include clarifying the role of depression and antidepressant therapy (and the interaction between the two) on bone health, determining potential sources for serotonin in bone cells, identifying mechanisms to explain the impact of serotonin on bone and understanding how serotonin-transporter genetics impact bone.

Original languageEnglish (US)
Pages (from-to)213-222
Number of pages10
JournalFuture Rheumatology
Issue number2
StatePublished - Apr 2007


  • Antidepressant medications
  • Bone mineral density
  • Depression
  • Fractures
  • Osteoporosis
  • Selective serotonin uptake inhibitors
  • Serotonin
  • Serotonin transporter

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Selective serotonin reuptake inhibitors and bone health'. Together they form a unique fingerprint.

Cite this